Incyte Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INCY research report →
Range $104 – $157
Price Chart
About the company
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates.
- CEO
- William J. Meury
- IPO
- 1993
- Employees
- 2,844
- HQ
- Wilmington, DE, US
AI snapshot
Six angles, distilled from the data.
The stock is in a constructive long-term uptrend, trading above its 200-day average of 108.92 and 50-day average of 119.18. It sits well below the 52-week high of 132.60 but far above the 52-week low of 89.25, which keeps the regime bullish with room to recover toward prior highs.
Street sentiment is constructive: consensus sits at Buy with a 137.81 average target, above the current share price. Recent action has been mostly target raises and reiterated positive calls, including upgrades and multiple $140-$157 targets, while the broader rating mix remains tilted to Buy and Hold.
The earnings cadence has been strong, with 6 beats in the last 8 quarters and a 59.1% EPS surprise in the most recent full quarter. Next-year EPS estimates are still elevated versus TTM EPS, so shareholders should watch whether management can sustain that step-up in profitability and convert it into cleaner guidance.
Recent insider activity leans negative on the surface, but it is concentrated in one executive and mixed with heavy exempt award-related entries. The only clear discretionary signals are three sales by Steven H. Stein, while the repeated M-Exempt transactions look like compensation-related activity rather than a broad insider exodus.
Profitability is solid, with a 56.0% gross margin and 32.22% operating margin, while revenue grew 14% year over year and EPS grew 37.7%. The balance sheet is strong too, with $3.58 billion in cash against just $40.4 million of debt, leaving a large net cash position.
INCY screens as a profitable biotech with better balance-sheet flexibility than many peers, supported by positive free cash flow of $1.47 billion and a 5.97% FCF yield. Valuation is not stretched for the group at 16.17x earnings, especially with analyst targets clustering above the current price.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $23.36B
- P/E
- 56.10
- Fwd P/E
- 35.62
- PEG
- -0.85
- P/S
- 3.99
- P/B
- 4.24
- EV/EBITDA
- 23.80
- Div Yield
- 0.00%
- Gross Margin
- 92.69%
- Op Margin
- 11.61%
- Net Margin
- 6.71%
- ROE
- 7.11%
- ROIC
- 6.03%
Latest fiscal year · YoY change
- Revenue
- $5.14B+21.2%
- Gross Profit
- $4.77B+21.4%
- Op Income
- $1.34B
- Net Income
- $1.29B+3845.0%
- EPS
- $6.59+4018.8%
- OCF Growth
- +321.5%
- FCF Growth
- +443.9%
- 52W High
- $132.60
- 52W Low
- $89.25
- 50D MA
- $118.63
- 200D MA
- $109.25
- Beta
- 0.78
- RSI (14)
- 44
- Avg Volume
- 1.62M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Incyte posted a strong third quarter with broad product growth, raised full-year sales guidance, and highlighted a much deeper late-stage pipeline across hematology, oncology, and dermatology.· October 29, 2026
- Total revenue was $1.56 billion, up 14% year over year, and total net sales were $1.32 billion, also up 14%.
- Jakafi franchise net sales were $827 million, up 4%, while core business net sales excluding Jakafi rose 30% to $490 million.
- OPZELURA net sales reached $255 million, up 36% reported and 21% on a pro forma basis; management said U.S. demand growth was strong.
- The company raised full-year 2026 guidance for OPZELURA, hematology and oncology, and total net sales.
- Management emphasized multiple phase III programs and near-term catalysts, including 989 in MF, povorcitinib in HS, and late-stage oncology readouts and initiations.
In the third quarter, total revenue was $1.56 billion, up 14% year over year, and total net sales were $1.32 billion, up 14% versus the prior year. Jakafi franchise net sales were $827 million, up 4% year over year, and core business net sales excluding Jakafi were $490 million, up 30%. OPZELURA net sales were $255 million, up 36% year over year, with U.S. net sales of $208 million, up 45% year over year; management also said U.S. net sales were up 25% on a pro forma basis, with 24% overall demand growth. GAAP cost of goods sold was $109 million, about 8% of total net sales, GAAP R&D was $1.79 billion, and GAAP SG&A was $364 million; total GAAP expenses were $2.27 billion, including a $1.23 billion IPR&D expense tied to the Vega acquisition. The company ended the quarter with $3.9 billion in cash and cash equivalents. For full-year 2026, management raised OPZELURA net sales guidance to $1.1 billion-$1.12 billion, hematology and oncology guidance to $890 million-$910 million, and total net sales guidance to $5.210 billion-$5.300 billion; operating expense guidance was maintained.
Bill Meury framed the quarter around scaling the core business beyond Jakafi and advancing a late-stage pipeline that can support growth into the 2030s. He said the company is increasingly focused on execution risk it can control, such as running trials well, enrolling on time, and hitting regulatory milestones. His tone was confident and strategic, emphasizing that Incyte now has multiple phase III assets and that the pipeline has become more diversified and mature over the last year.
Suky Upadhyay said the company delivered strong net sales, managed expenses, and is raising full-year sales outlooks while holding operating expense guidance steady. She cited $1.56 billion of revenue, $1.32 billion of net sales, $2.27 billion of GAAP expenses, and $3.9 billion of cash and cash equivalents at quarter-end. She noted that the $1.23 billion IPR&D charge from the Vega acquisition drove the big jump in GAAP expenses, and that excluding Vega-related IPR&D, operating expenses were up 12%; COGS remained approximately 8% of net sales and is expected to stay around 8% for the full year.
Analysts focused on 989 and CALR data, including what the company needs to see before finalizing frontline MF study design and how prior Jakafi exposure is defined in second-line disease. Management said the ASH update will include about 55 frontline patients and emphasized that the data presentation will be more mature than the abstract; they also said second-line enrollment has no minimum Jakafi duration and physicians will determine intolerance or inadequate response. Other questions centered on OPZELURA demand and gross-to-net, where management said U.S. growth is being driven mainly by demand, not pricing, and on povorcitinib labeling, where they said both pre- and post-biologic label scenarios are workable. Management also explained the CDK2 decision as driven by difficult accrual and limited commercial prospects in platinum-resistant ovarian cancer, and said the next-generation CALR and V617F programs are moving toward clinic in early 2027.
The quarter showed broad-based growth: every product grew year over year, core business ex-Jakafi rose 30%, and OPZELURA demand remained strong. Management also raised full-year sales guidance and highlighted a pipeline with several phase III shots on goal, plus near-term data and regulatory catalysts.
The company is absorbing a large Vega acquisition charge, with $1.23 billion of IPR&D expense lifting GAAP costs sharply, and operating expenses remain elevated because of late-stage development and pre-launch spending. Management also acknowledged real program-specific risks: the CDK2 program in platinum-resistant ovarian cancer is being deprioritized, some assets still need FDA alignment on endpoints, and several of the most important readouts are still ahead.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.1%
- Shares Outstanding
- 203.83M
- Float Shares
- 201.97M
of shares held by institutions
882 13F filers
Buy/sell ratio 0.63. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for INCY, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Oct 7, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 4, 26 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | May 15, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 9, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Mar 25, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 2, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 10, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 6, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jun 26, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jun 29, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 19, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Mar 6, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Mar 14, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 9, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Baker Bros. Advisors LP | 30.76M | ▲ 17.92K |
| Vanguard Group Inc | 19.91M | ▼ 40.19K |
| Blackrock, Inc. | 19.13M | ▲ 1.10M |
| Vanguard Capital Management LLC | 11.22M | ▲ 198.77K |
| Dodge & Cox | 10.06M | ▼ 1.89M |
| State Street Corp | 9.86M | ▲ 135.95K |
| Vanguard Portfolio Management LLC | 7.77M | ▼ 18.00K |
| Aqr Capital Management LLC | 5.32M | ▼ 487.03K |
| Geode Capital Management, LLC | 4.89M | ▲ 139.92K |
| Invesco Ltd. | 4.14M | ▲ 56.62K |
| Lsv Asset Management | 3.88M | ▼ 242.36K |
| Wellington Management Group Llp | 3.58M | ▲ 309.38K |
Held by 1,893 ETFs
Biggest fund positions in INCY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Stein Steven H | other | 576 |
| Nov 16, 26 | Stein Steven H | sell | 576 |
| Nov 16, 26 | Stein Steven H | other | 576 |
| Nov 16, 26 | CAGNONI PABLO J | other | 839 |
| Nov 16, 26 | CAGNONI PABLO J | other | 926 |
| Nov 16, 26 | CAGNONI PABLO J | sell | 877 |
| Nov 16, 26 | CAGNONI PABLO J | other | 422 |
| Nov 16, 26 | CAGNONI PABLO J | other | 455 |
| Nov 16, 26 | CAGNONI PABLO J | sell | 1,765 |
| Nov 16, 26 | CAGNONI PABLO J | other | 926 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INCY coverage
Recent articles, reports, and earnings notes.

Devonian Health Group IPO: The Bull and Bear Case
Devonian Health Group Inc. (NYSE: DHGR) is expected to list on 2026-08-21, but the company has not disclosed a price range yet. The setup is a clinical-stage biotech story with a commercial distribution business behind it, which gives it a real revenue base but also a financing-heavy path ahead.

Latigo Biotherapeutics IPO: The Bull and Bear Case
Latigo Biotherapeutics, Inc. (NASDAQ: LTGO) is expected to list on 2026-08-07 at a price range of $16.00 to $18.00 per share. The company is offering 16,000,000 shares, with a disclosed market cap of $331.2 million. The bull case is a differentiated non-opioid pain platform; the bear case is a clinical-stage biotech with no revenue, rising losses, and a long road to approval.

Incyte is getting sold like a one-drug story even as the second act gets closer
Incyte is still being traded like Jakafi is the whole story, and that framing is getting stale. Revenue grew 21% in Q1, Jakafi XR is already approved, and a September FDA catalyst gives the pipeline a much more investable shape than the stock seems to reflect.
Want a deeper read on INCY?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Incyte Maps Post-JAKAFI Growth as Key Drug Data and 2027 Launch Loom
marketbeat.com · Nov 20
Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
INCY Wins European Commission Nod For Skin Disease Drug
zacks.com · Nov 17
Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 17
Incyte says EU approves oral treatment for chronic skin disease
reuters.com · Nov 16
Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa
businesswire.com · Nov 16
Incyte Corporation $INCY Stock Position Cut by Eurizon Capital SGR S.p.A.
defenseworld.net · Nov 15
Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030
marketbeat.com · Nov 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 16, 2026 · Live quote · Not investment advice